Share on StockTwits

DaVita HealthCare Partners (NYSE:DVA) shares hit a new 52-week high during mid-day trading on Friday , Stock Ratings News reports. The company traded as high as $74.99 and last traded at $74.89, with a volume of 275,000 shares traded. The stock had previously closed at $74.42.

DVA has been the subject of a number of recent research reports. Analysts at Deutsche Bank downgraded shares of DaVita HealthCare Partners from a “buy” rating to a “hold” rating in a research note on Friday, August 15th. They now have a $77.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at Zacks reiterated a “neutral” rating on shares of DaVita HealthCare Partners in a research note on Friday, August 1st. They now have a $74.00 price target on the stock. Finally, analysts at Raymond James downgraded shares of DaVita HealthCare Partners from an “outperform” rating to a “market perform” rating in a research note on Monday, July 21st. They now have a $75.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $75.33.

The stock has a 50-day moving average of $72.61 and a 200-day moving average of $70.05. The company has a market cap of $16.026 billion and a price-to-earnings ratio of 23.56.

DaVita HealthCare Partners (NYSE:DVA) last announced its earnings results on Thursday, July 31st. The company reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.06. The company had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.10 billion. During the same quarter in the previous year, the company posted $1.84 earnings per share. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. Analysts expect that DaVita HealthCare Partners will post $3.62 EPS for the current fiscal year.

DaVita HealthCare Partners Inc, formerly DaVita Inc, is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (NYSE:DVA).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.